Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 15;2014(5):CD003948.
doi: 10.1002/14651858.CD003948.pub3.

Topical agents and dressings for fungating wounds

Una J Adderley  1 , Ian G S Holt
Affiliations

Topical agents and dressings for fungating wounds

Una J Adderley et al. Cochrane Database Syst Rev. .

Abstract

Background: Fungating wounds arise from primary, secondary or recurrent malignant disease and are associated with advanced cancer. A small proportion of patients may achieve healing following surgical excision, but treatment is usually palliative. Fungating wound management usually aims to slow disease progression and optimise quality of life by alleviating physical symptoms, such as copious exudate, malodour, pain and the risk of haemorrhage, through selection of appropriate dressings and topical agents.

Objectives: To review the evidence of the effects of dressings and topical agents on quality of life, and symptoms that impact on quality of life, in people with fungating malignant wounds.

Search methods: For this third update we searched the Wounds Group Specialised Register in August 2013; the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid EMBASE and EBSCO CINAHL.

Selection criteria: Eligible studies comprised randomised controlled trials (RCTs) or, in their absence, controlled clinical trials (CCTs) with a concurrent control group.

Data collection and analysis: Data extraction and risk of bias assessment was undertaken by one review author and checked for accuracy by a second.

Main results: Four trials involving 164 people were included. One RCT in women with superficial breast lesions compared 6% miltefosine solution with placebo and found that miltefosine delayed tumour progression. The study reported that the time to treatment failure was significantly longer in the miltefosine group (median 56 days) than in the placebo group (median 21 days) (p value 0.007, log-rank test). A second trial compared topical metronidazole with placebo but the results up to the point of cross-over were not statistically significant. A third trial compared the effect of foam dressings containing silver to foam dressings without silver and found that more patients experienced decreased malodour in the foam with silver group than in the foam alone group (p value=0.049). The fourth trial compared the effect of manuka honey-coated dressings with nanocrystalline silver-coated dressings and found no statistically significant difference with regard to exudate, malodour and wound pain. All trials, however, had methodological limitations.

Authors' conclusions: There is weak evidence from one small trial that 6% miltefosine solution applied topically to people with superficial fungating breast lesions (smaller than 1cm) who have received either previous radiotherapy, surgery, hormonal therapy or chemotherapy for their breast cancer, may slow disease progression. There is also weak evidence to suggest that foam dressings containing silver may be effective in reducing malodour. There is insufficient evidence in this review to give a clear direction for practice with regard to improving quality of life or managing wound symptoms associated with fungating wounds. More research is needed.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

1
1
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Bower 1992 {published data only}
    1. Bower M, Stein R, Evans TR, Hedley A, Pert P, Coombes RC. A double‐blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumours. European Journal of Cancer 1992;28A(4‐5):888‐9. - PubMed
Kalemikerakis 2012 {published data only}
    1. Kalemikerakis J. Comparison of foam dressings with silver versus foam dressings without silver in the care of malodorous malignant fungating wounds. Journal of B.U.On 2012;17(3):560‐4. - PubMed
Leonard 2001 {published data only}
    1. Leonard R, Hardy J, Tienhoven G, Houston S, Simmonds P, David M, et al. Randomized, double‐blind, placebo‐controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. Journal of Clinical Oncology 2001;19(21):4150‐9. - PubMed
Lund‐Nielsen 2011a {published data only}
    1. Lund‐Nielsen B, Adamsen L, Kolmos HJ, Rorth M, Tolver A, Gottrup F. The effect of honey‐coated bandages compared with silver‐coated bandages on treatment of malignant wounds ‐ a randomized study. Wound Repair and Regeneration 2011;19(6):664‐70. - PubMed

References to studies excluded from this review

Ashford 1984 {published data only}
    1. Ashford R, Plant G, Maher J, Teare L. Double blind trial of metronidazole in malodorous ulcerating tumours. Lancet 1984;June 2:1232‐3. - PubMed
Bale 2004 {published and unpublished data}
    1. Bale S, Tebbie N, Price P. A topical metronidazole gel used to treat malodorous wounds. British Journal of Nursing 2004;13(11):4S‐11S. - PubMed
Clive 1999 {published data only}
    1. Clive S, Gardiner J, Leonard RC. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. Cancer Chemotherapy Pharmacology 1999;44(Suppl):29S‐30S. - PubMed
Efendiev 1991 {published data only}
    1. Efendiev AI, Tolstykh PI, Dadashev AI, Marshava AM. Topical prolonged enzyme therapy of purulent wounds. Khirurgiia (Mosk) 1991;Jul(7):48‐50. - PubMed
Gostishchev 1983 {published data only}
    1. Gostishchev VK, Vasilkova ZF, Khanin AG, Vavilova GS, Lebedskoj AG. Debrisan in the treatment of purulent wounds. Vestnik Chirurgii Imemi Grekova 1983;131(9):56‐9. - PubMed
Gostishchev 1985 {published data only}
    1. Gostishchev VK, Tolstykh PI, Khanin AG, Vasilkova ZF, Yusupuv KA, Vlasov, LT, et al. The use of Trypsin immobilised on textile cellulose matrix in the treatment of purulent wounds of soft tissues. Vestnik Chirurgii Imemi Grekova 1985;134(6):68‐71. - PubMed
Gostishchev 1993 {published data only}
    1. Gotstishchev VK, Mulyaev LF, Nikolaev AV, Khanin AG, Kassin VY. Regenkur, a polymer sorbent, in the treatment of purulent wounds. Khirurgiya 1993;69(11):3‐6. - PubMed
Grocott 2001a {published data only}
    1. Grocott P, Cowley S. The palliative management of fungating malignant wounds ‐ generalising from multiple‐case study data using a system of reasoning. International Journal of Nursing Studies 2001;38(5):533‐45. - PubMed
Healy 1969 {published data only}
    1. Healy JB. The use of topical 5‐fluorouracil. Journal of the Irish Medical Association 1969;62(380):41‐6. - PubMed
Ingle 2006 {published data only}
    1. Ingle R, Levin J, Polinder K. Wound healing with honey ‐ a randomised controlled trial. South African Medical Journal 2006;96(9):831‐5. - PubMed
Lo 2010 {published data only}
    1. Lo SF. A cost‐effectiveness analysis of a silver dressing for malignant fungating wound of cancer patients. EWMA Journal 2010;10:P116.
Lo 2010a {published data only}
    1. Lo SF, Huang CU. The effect wound bed status of a ionic silver dressings in cancer patients with malignant fungating wound. EWMA Journal. 2010; Vol. 10:P28.
Lo 2012 {published data only}
    1. Lo S‐F, Hayter M, Hu W‐Y, Tai C‐Y, Hsu M‐Y, Li Y‐F. Symptom burden and quality of life in patients with malignant fungating wounds. Journal of Advanced Nursing 2012;68(6):1312‐21. - PubMed
Lund‐Nielsen 2008 {published data only}
    1. Lund‐Nielsen B. Malignant wounds. A randomised clinical trial investigating a complimentary multidimensional intervention. EWMA Conference. 2008; Vol. 8, issue 2 (Supp):49, Abstract no. 60.
Lund‐Nielsen 2011 {published data only}
    1. Lund‐Nielsen B, Adamsen L, Gottrup F, Rorth M, Tolver A, Kolmos HJ. Qualitative bacteriology in malignant wounds ‐ A prospective randomized clinical study to compare the effect of honey and silver dressings. Ostomy/Wound Management 2011;57(7):28‐36. - PubMed
Moller 2000 {published data only}
    1. Moller F, Jakobsen V, Jensen K. Performance of Contreet antibacterial hydrocolloid dressing compared to other antibacterial dressings. Tenth Annual Meeting of the European Tissue Repair Society; 2000, 24‐27 May; Brussels, Belgium. Brussels, 2000:A427.
Russell 2001 {published data only}
    1. Russell L, Deeth M, Jones HM, Reynolds T. Vacutex capillary action dressing: a multicentre, randomized trial. British Journal of Nursing 2001;10(11):66S‐70S. - PubMed
Stuwe 1983 {published data only}
    1. Stuwe VU. Enzymatische wundreinigung. Fortschritte des Medizin 1983;101(41):1883‐8. - PubMed
Taranenko 1984 {published data only}
    1. Taranenko LD, Bondarev VI, Nefedov GP, Shlopov VG, Verkhuletsky IE, Kuznetsov AS. Experience in the use of SKN‐1K sorbent in the treatment of purulent wounds. Klinichna Khirurhiia 1984;Jan(1):44‐7. - PubMed
Udwadia 2011 {published data only}
    1. Udwadia TE. Ghee and honey dressing for infected wounds. Indian Journal of Surgery 2011;73(4):278‐83. - PMC - PubMed
Upright 1994 {published data only}
    1. Upright CA, Salton C, Roberts F, Murphy J. Evaluation of Mesalt dressings and continuous wet saline dressings in ulcerating metastatic skin lesions. Cancer Nursing 1994;17(2):149‐55. - PubMed

Additional references

Alexander 2009a
    1. Alexander S. Malignant fungating wounds: epidemiology, aetiology, presentation and assessment. Journal of Wound Care 2009;18(7):273‐80. - PubMed
Alexander 2009b
    1. Alexander S. Malignant fungating wounds: key symptoms and psychosocial. Journal of Wound Care 2009;18(8):325‐9. - PubMed
Bale 1991
    1. Bale S, Harding K. Fungating breast wounds. Journal of District Nursing 1991;9(12):4‐5.
Bridel‐Nixon 1997
    1. Bridel‐Nixon J. Other chronic wounds. In: Morison M, Moffatt C, Bridel‐Nixon J, Bale S editor(s). Nursing Management of Chronic Wounds. 1st Edition. London: Mosby, 1997:221‐45.
de Haes 1996
    1. Haes JCJM de, Olschewski M, Fayers P, Visser MRM, Cull A, Hopwood P, Sanderman, R. Measuring the quality of life of cancer patients with the Rotterdam Symptom Checklist: a manual. Groningen, the Netherlands: Noordelijk Centrum voor Gezondheidsvraagstukken / Northern Centre for Healthcare Research. University of Groningen, 1996.
Fairburn 1994
    1. Fairburn K. A challenge that requires further research. Management of fungating breast lesions. Professional Nurse 1994;9:272‐7. - PubMed
Gibson 2013
    1. Gibson S, Green J. Review of patients' experiences with fungating wounds and associated quality of life. Journal of Wound Care 2013;22(5):265‐75. - PubMed
Grocott 1995
    1. Grocott P. The palliative management of fungating malignant wounds. Journal of Wound Care 1995;4(5):240‐2. - PubMed
Grocott 2001b
    1. Grocott P. Developing a tool for researching fungating wounds. World Wide Wounds 2001; Vol. http://www.worldwidewounds.com/2001/july/Grocott/Fungating‐Wounds.html.
Grocott 2002
    1. Grocott P. A review of advances in fungating wound management since EWMA 1991. EWMA Journal 2002;2(1):21‐4.
Haughton 1995
    1. Haughton W, Young T. Common problems in wound care: malodorous wounds. British Journal of Nursing 1995;4(16):959‐63. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (Editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Available from www.cochrane‐handbook.org.
Hirst 1992
    1. Hirst DG. Tumour vascular physiology. Annual report of the Cancer Research Campaign Grey Laboratory 1992.
Kelly 2002
    1. Kelly N. Malodorous fungating wounds: a review of current literature. Professional Nurse 2002;17(5):323‐6.
KLONK 2014
    1. KLONK. KLONK Image Measurement. http://www.imagemeasurement.com/ (accessed February 15 2014).
Lefebrve 2011
    1. Lefebvre C, Manheimer E, Glanville J, on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Lo 2008
    1. Lo S, Hu W, Hayter M, Chang SC, Hsu MY, Wu LY. Experiences of living with a malignant fungating wound: a qualitative study.. Journal of Clinical Nursing 2008;17(20):2699‐708. - PubMed
Lund‐Nielson 2005
    1. Lund‐Nielsen B, Muller K, Adamsen L. Malignant wounds in women with breast cancer: feminine and sexual perspectives. Journal of Clinical Nursing 2005;14:56‐64. - PubMed
Melzack 1987
    1. Melzack R. The short‐form McGill Pain Questionnaire. Pain 1987;30(2):191‐7. - PubMed
Probst 2013
    1. Probst S, Arber A, Faithfull S. Coping with an exulcerated breast carcinoma: an interpretative phenomenological study. Journal of Wound Care 2013;22(7):352‐60. - PubMed
Selby 2009
    1. Selby T. Managing exudate in malignant fungating wounds and solving problems for patients. Nursing Times 2009;105(18):14‐17. - PubMed
SIGN 2008
    1. Scottish Intercollegiate Guidelines Network (SIGN). Search filters. Available from http://www.sign.ac.uk/methodology/filters.html#random (accessed August 2008).
WHO 1979
    1. World Health Organisation. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organisation, 1979.

Publication types

MeSH terms

LinkOut - more resources